Literature DB >> 10464621

Canavan disease: diagnosis and molecular analysis.

R Matalon1.   

Abstract

Canavan disease, spongy degeneration of the brain, is an autosomal recessive disorder with increased prevalence among Ashkenazi Jews. The biochemical marker for this disease is increased levels of N-acetylaspartic acid, due to the defective enzyme, aspartoacylase. This discovery allowed for accurate diagnosis of the disease. The gene for aspartoacylase has been cloned and two mutations have been found to be responsible for Canavan disease among Ashkenazi Jewish patients in 98% of the cases. Molecular analysis of healthy Jewish individuals for these mutations has resulted in an unexpectedly high carrier frequency for Canavan disease among Jews. Therefore, carrier testing of the Jewish population is possible and indicated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 10464621     DOI: 10.1089/gte.1997.1.21

Source DB:  PubMed          Journal:  Genet Test        ISSN: 1090-6576


  7 in total

Review 1.  Biochemistry and molecular biology of Canavan disease.

Authors:  R Matalon; K Michals-Matalon
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

2.  Development of genomic DNA reference materials for genetic testing of disorders common in people of ashkenazi jewish descent.

Authors:  Lisa Kalman; Jean Amos Wilson; Arlene Buller; John Dixon; Lisa Edelmann; Louis Geller; William Edward Highsmith; Leonard Holtegaard; Ruth Kornreich; Elizabeth M Rohlfs; Toby L Payeur; Tina Sellers; Lorraine Toji; Kasinathan Muralidharan
Journal:  J Mol Diagn       Date:  2009-10-08       Impact factor: 5.568

Review 3.  Structures of proteins of biomedical interest from the Center for Eukaryotic Structural Genomics.

Authors:  George N Phillips; Brian G Fox; John L Markley; Brian F Volkman; Euiyoung Bae; Eduard Bitto; Craig A Bingman; Ronnie O Frederick; Jason G McCoy; Betsy L Lytle; Brad S Pierce; Jikui Song; Simon N Twigger
Journal:  J Struct Funct Genomics       Date:  2007-09-06

4.  Structure of aspartoacylase, the brain enzyme impaired in Canavan disease.

Authors:  Eduard Bitto; Craig A Bingman; Gary E Wesenberg; Jason G McCoy; George N Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-28       Impact factor: 11.205

5.  The natural history of Canavan disease: 23 new cases and comparison with patients from literature.

Authors:  Annette Bley; Jonas Denecke; Alfried Kohlschütter; Gerhard Schön; Sandra Hischke; Philipp Guder; Tatjana Bierhals; Heather Lau; Maja Hempel; Florian S Eichler
Journal:  Orphanet J Rare Dis       Date:  2021-05-19       Impact factor: 4.123

Review 6.  Canavan's spongiform leukodystrophy: a clinical anatomy of a genetic metabolic CNS disease.

Authors:  M H Baslow
Journal:  J Mol Neurosci       Date:  2000-10       Impact factor: 2.866

7.  Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity.

Authors:  Marisa I Mendes; Desirée Ec Smith; Ana Pop; Pascal Lennertz; Matilde R Fernandez Ojeda; Warsha A Kanhai; Silvy Jm van Dooren; Yair Anikster; Ivo Barić; Caroline Boelen; Jaime Campistol; Lonneke de Boer; Ariana Kariminejad; Hulya Kayserili; Agathe Roubertie; Krijn T Verbruggen; Christine Vianey-Saban; Monique Williams; Gajja S Salomons
Journal:  Hum Mutat       Date:  2017-02-14       Impact factor: 4.878

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.